New antithrombotics in the treatment of thromboembolic disease

European Journal of Internal Medicine

Volumn 16, Issue 4, 2005, Pages 230-237

  Levi, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antithrombotics; Melagatran; Pentasaccharide

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; COUMARIN DERIVATIVE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; IDRAPARINUX; LIVER ENZYME; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PENTASACCHARIDE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; THROMBIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENZYME BLOOD LEVEL; FOLLOW UP; HEART INFARCTION; HUMAN; LUNG EMBOLISM; ORTHOPEDIC SURGERY; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATION; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 23444455447     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2004.11.009     Document Type: Conference Paper

References (43)

1. N. Strebel, M. Prins, G. Agnelli, and H.R. Buller Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 162 2002 1451 1456
2. M. Cohen Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update Drugs 62 2002 1755 1770
3. R.F. van Es, J.J. Jonker, F.W. Verheugt, J.W. Deckers, and D.E. Grobbee Aspirin and coumadin after acute coronary syndromes the ASPECT-2 study.: a randomised controlled trial Lancet 360 2002 109 113
4. van der Meer, H.L. Hillege, and G.J. Kootstra Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands Lancet 342 1993 257 264
5. M. Levi, R.J. Peters, J.J. Piek, and H.R. Buller New anticoagulants Ned Tijdschr Geneeskd 147 2003 909 915
6. B.J. Biemond, P.W. Friederich, and M. Levi Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis Circulation 93 1996 153 160
7. E. Abraham, K. Reinhart, and P. Svoboda Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study Crit Care Med 29 2001 2081 2089
8. E. Abraham, K. Reinhart, and S. Opal Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial JAMA 290 2003 238 247
9. A. Lee, G. Agnelli, and H. Buller Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement Circulation 104 2001 74 78
10. A.H. Moons, R.J. Peters, and N.R. Bijsterveld Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty J Am Coll Cardiol 41 2003 2147 2153
11. K.A. Bauer, D.W. Hawkins, and P.C. Peters Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents-the selective factor Xa inhibitors Cardiovasc Drug Rev 20 2002 37 52
12. M.M. Samama, and G.T. Gerotziafas Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux) Thromb Res 109 2003 1 11
13. M.M. Koopman, and H.R. Buller Short- and long-acting synthetic pentasaccharides J Intern Med 254 2003 335 342
14. A.G. Turpie, A.S. Gallus, and J.A. Hoek A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement N Engl J Med 344 2001 619 625
15. M.R. Lassen, K.A. Bauer, B.I. Eriksson, and A.G. Turpie Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison Lancet 359 2002 1715 1720
16. A.G. Turpie, K.A. Bauer, B.I. Eriksson, and M.R. Lassen Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial Lancet 359 2002 1721 1726
17. K.A. Bauer, B.I. Eriksson, M.R. Lassen, and A.G. Turpie Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery N Engl J Med 345 2001 1305 1310
18. B.I. Eriksson, K.A. Bauer, M.R. Lassen, and A.G. Turpie Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery N Engl J Med 345 2001 1298 1304
19. A.G. Turpie, K.A. Bauer, B.I. Eriksson, and M.R. Lassen Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies Arch Intern Med 162 2002 1833 1840
20. R. Collins, A. Scrimgeour, S. Yusuf, and R. Peto Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery N Engl J Med 318 1988 1162 1173
21. P. Mismetti, S. Laporte-Simitsidis, and B. Tardy Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials Thromb Haemost 83 2000 14 19
22. Treatment of proximal deep vein thrombosis with a novel synthetic compound SR90107A/ORG31540 with pure anti-factor Xa activity: a phase II evaluation. The Rembrandt Investigators Circulation 102 2000 2726 2731
23. H.R. Buller, B.L. Davidson, and H. Decousus Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial Ann Intern Med 140 2004 867 873
24. H.R. Buller, B.L. Davidson, and H. Decousus Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism N Engl J Med 349 2003 1695 1702
25. P.K. Coussement, J.P. Bassand, and C. Convens A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study Eur J Heart 22 2001 1716 1724
26. M.L. Simoons, I.W. Bobbink, and J. Boland A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study J Am Coll Cardiol 43 2004 2183 2190
27. N.R. Bijsterveld, A.H. Moons, and S.M. Boekholdt Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers Circulation 106 2002 2550 2554
28. N.R. Bijsterveld, R. Vink, and B.E. van Aken Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers Br J Haematol 124 2004 653 658
29. J.I. Weitz, and H.R. Buller Direct thrombin inhibitors in acute coronary syndromes: present and future Circulation 105 2002 1004 1011
30. K. Wahlander, L. Lapidus, and C.G. Olsson Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis Thromb Res 107 2002 93 99
31. C.W. Francis Ximelagatran: a new oral anticoagulant Best Pract Res Clin Haematol 17 2004 139 152
32. B.I. Eriksson, D. Bergqvist, and P. Kalebo Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial Lancet 360 2002 1441 1447
33. B.I. Eriksson, G. Agnelli, and A.T. Cohen The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study J Thromb Haemost 1 2003 2490 2496
34. B.I. Eriksson, G. Agnelli, and A.T. Cohen Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement Thromb Haemost 89 2003 288 296
35. C.W. Francis, B.L. Davidson, and S.D. Berkowitz Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial Ann Intern Med 137 2002 648 655
36. C.W. Francis, S.D. Berkowitz, and P.C. Comp Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement N Engl J Med 349 2003 1703 1712
37. C.W. Colwell Jr., S.D. Berkowitz, and B.L. Davidson Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study J Thromb Haemost 1 2003 2119 2130
38. H. Eriksson, K. Wahlander, and D. Gustafsson A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I J Thromb Haemost 1 2003 41 47
39. J.H. Geest-Daalderop, A. Sturk, M. Levi, and H.J. Adriaansen Extent and quality of anti-coagulation treatment with coumarin derivatives by the Dutch Thrombosis Services Ned Tijdschr Geneeskd 148 2004 730 735
40. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
41. J.L. Halperin Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) Am Heart J 146 2003 431 438
42. L. Wallentin, R.G. Wilcox, and W.D. Weaver Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
43. M. Woltz, M. Levi, and T.C. Sarich Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers Thromb Haemost 91 2004 1090 1096